Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Amgen Inc (AMGN)

Amgen Inc (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 119,055,848
  • Shares Outstanding, K 567,852
  • Annual Sales, $ 25,424 M
  • Annual Income, $ 7,264 M
  • 60-Month Beta 0.69
  • Price/Sales 4.62
  • Price/Cash Flow 8.99
  • Price/Book 14.24
Trade AMGN with:

Options Overview Details

View History
  • Implied Volatility 24.48%
  • Historical Volatility 18.13%
  • IV Percentile 55%
  • IV Rank 28.96%
  • IV High 42.23% on 10/28/20
  • IV Low 17.25% on 06/17/21
  • Put/Call Vol Ratio 0.54
  • Today's Volume 2,877
  • Volume Avg (30-Day) 6,946
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 62,270
  • Open Int (30-Day) 85,181

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 4.10
  • Number of Estimates 10
  • High Estimate 4.45
  • Low Estimate 3.17
  • Prior Year 4.37
  • Growth Rate Est. (year over year) -6.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
200.47 +4.25%
on 10/12/21
216.80 -3.60%
on 09/29/21
-6.37 (-2.96%)
since 09/21/21
3-Month
200.47 +4.25%
on 10/12/21
248.56 -15.92%
on 07/23/21
-35.86 (-14.65%)
since 07/21/21
52-Week
200.47 +4.25%
on 10/12/21
276.69 -24.47%
on 01/28/21
-19.98 (-8.73%)
since 10/21/20

Most Recent Stories

More News
Radius (RDUS) Up On Positive Data From Breast Cancer Study

Radius (RDUS) stock gains in response to positive results from a late-stage study evaluating breast cancer candidate, elacestrant.

REGN : 569.37 (+1.18%)
LLY : 241.17 (-1.05%)
AMGN : 208.99 (-0.32%)
RDUS : 19.40 (+7.84%)
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Amgen (AMGN) closed at $206.78, marking a +1.8% move from the previous day.

AMGN : 208.99 (-0.32%)
Esperion (ESPR) to Cut 40% Workforce, Revamp Cost Structure

Esperion (ESPR) is set reduce its workforce by 40% and start targeted program savings to reduce its operational expense and deliver consistent growth.

REGN : 569.37 (+1.18%)
MRK : 81.17 (+0.12%)
AMGN : 208.99 (-0.32%)
ESPR : 8.97 (-4.98%)
Amgen Successfully Completes Acquisition Of Teneobio, Inc.

/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of Teneobio, Inc. (Teneobio)....

AMGN : 208.99 (-0.32%)
Zacks Market Edge Highlights: AT&T, Verizon, Amgen, Poshmark, and The RealReal

Zacks Value Trader Highlights: AT&T, Verizon, Amgen, Poshmark, and The RealReal

T : 25.76 (-0.58%)
VZ : 53.39 (-0.41%)
AMGN : 208.99 (-0.32%)
REAL : 13.10 (+1.55%)
POSH : 26.28 (+4.08%)
How to Find Stocks on Sale in 2021

Looking for hidden gems isn't too hard with this simple stock screen.

T : 25.76 (-0.58%)
VZ : 53.39 (-0.41%)
AMGN : 208.99 (-0.32%)
REAL : 13.10 (+1.55%)
POSH : 26.28 (+4.08%)
Amgen (AMGN) Reports New Data From Lumakras Combo Study

Amgen (AMGN) reports new combination data from the phase Ib CodeBreaK 101 study. It also buys a stake in Neumora Therapeutics to advance novel therapies for brain diseases.

REGN : 569.37 (+1.18%)
AMGN : 208.99 (-0.32%)
VRTX : 187.09 (+0.86%)
HZNP : 116.46 (+2.43%)
Bristol Myers (BMY) UC Candidate Fails in Phase II Study

Bristol Myers (BMY) suffers a setback as its phase II study of deucravacitinib for the treatment of moderate to severe ulcerative colitis fails to meet primary and secondary endpoints.

RHHBY : 48.8400 (+2.26%)
BMY : 57.81 (-0.45%)
MRK : 81.17 (+0.12%)
AMGN : 208.99 (-0.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Key Turning Points

3rd Resistance Point 212.86
2nd Resistance Point 211.56
1st Resistance Point 210.28
Last Price 208.99
1st Support Level 207.69
2nd Support Level 206.38
3rd Support Level 205.10

See More

52-Week High 276.69
Fibonacci 61.8% 247.57
Fibonacci 50% 238.58
Fibonacci 38.2% 229.59
Last Price 208.99
52-Week Low 200.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar